Harpoon Therapeutics Inc

Harpoon Therapeutics — Technical Presentation (January 2024)

12 slides from Harpoon Therapeutics's technical presentation, Jan 26, 2024

  1. Slide 1: Interim Results from a Phase 1/2 Study of HPN328 in NEPC and Other NEN

    Interim Results from a Phase 1/2 Study of HPN328, a Tri-Specific, Half-Life (T1/2) Extended DLL3-targeting T-Cell Engager in Patients (pts) with Neuroendocrine Prostate Cancer (NEPC) and other Neuroendocrine Neoplasms (NEN) Himisha Beltran1, Afshin Dowlati2, Prantesh Jain3, Melissa Lynne Johnson4, R

  2. Slide 2: DLL3 Expression Across Prostate Cancer Stages

    76.6% (36/47) 12.5% (7/56) 0.52% (1/194) 0% (0/103) DLL3+ (%) Puca L et al., Sci. Transl. Med. (2019) Dr. Himisha Beltran

  3. Slide 3: HPN328 is a DLL3-targeting T Cell Engager with strong activity in DLL3+ cancer models

    Dr. Himisha Beltran HPN328 is a DLL3-targeting T Cell Engager with strong activity in DLL3+ cancer models WCM154 Weeks Anti-tumor activity in vivo: DLL3+ WCM154 Patient- Derived NEPC Xenografts HPN328 and co-injection with human T cells resulted in tumor regression and prolonged survival of mice

  4. Slide 4: HPN328 Trial Design and Baseline Characteristics

    HPN328 Trial Design and Baseline Characteristics Trial Design Dose escalation 3+3 design (total N=85) HPN328 is administered weekly or biweekly Dose optimization cohorts with 1mg priming dose (N=61) 6 mg QW 12 mg QW and Q2W 24 mg QW and Q2W Trial objectives Assess safety and tolerability Determine R

  5. Slide 5: Adverse Events in All Subjects Treated (N=85)

    Adverse Events in All Subjects Treated (N=85) Dr. Himisha Beltran Two DLTs seen at priming dose of 2 mg (G3 CRS, n=2), priming dose de-escalated to 1mg No DLTs observed at target doses; target dose MTD not reached Data snapshot date: 08Dec2023 ICANS=Immune effector cell-associated neurotoxicity synd

  6. Slide 6: Anti-tumor Activity in mg Priming Subjects Evaluable For Response

    Anti-tumor Activity in 1 mg Priming Subjects Evaluable For Response Dr. Himisha Beltran All Tumor Types (n=50*); Other GU NEC *Shown are subjects treated ithe 1mg priming dose optimization cohorts with at least 1 post-baseline scan, data cutoff = December 8, 2023 Using modified RECIST 1.1 to include

  7. Slide 7: Duration of Response and Treatment

    Dr. Himisha Beltran -82.6% † -34.3% -20.7% -31.6% -16.8% ✷ -78.3% -49.1% -37.2% -16.3% ✷ -100% † † Ongoing NEPC NEC GU Progressive Disease (PD) Stable Disease (SD) Partial Response (PR) Complete Response (CR) Off treatment for withdrawal of consent Off treatment due to AE unrelated to treatment or p

  8. Slide 8: NEPC patient with sustained decrease visceral target lesions, remained on therapy 11 months

    NEPC patient with sustained decrease visceral target lesions (TL), remained on therapy 11 months Presented with metastatic HSPC, PSA 35 ng/ml. Treated with ADT + abiraterone/prednisone 3.5 years later: new liver metastases, PSA 0.08 ng/ml Biopsy: high grade NEPC -> Carboplatin + Cabazitaxel x 10-> P

  9. Slide 9: Was clinical benefit driven by targeting more aggressive DLL3-positive clones?

    Was clinical benefit driven by targeting more aggressive DLL3-positive clones? Dr. Himisha Beltran NEPC patient with heterogeneous DLL3 expression Responding Lesion Progressing Lesion Progressing Lesion

  10. Slide 10: DLL3 Expression

    DLL3 Expression For NEPC and SCLC, DLL3 pre-screening not required Small cell bladder cancer (N=3); DLL3 expressed in 100% tumor cells For NEPC: Sites of archival tissue: prostate, lymph node, liver, bone, pleura NEPC pathology: pure small cell carcinoma, high grade NEC, mixed adeno/small cell (with

  11. Slide 11: Conclusions

    Dr. Himisha Beltran Conclusions HPN328 is a novel DLL3 T cell engager that is well tolerated and demonstrates promising clinical activity in NE carcinomas, including GU NEC Adverse events were manageable, with CRS most commonly occurring with the first dose, mostly grades 1 or 2 Monotherapy dose opt

  12. Slide 12: Acknowledgements

    Acknowledgements Thank you to our patients, their families, and our clinical site staff who continue to make this trial possible. Dr. Himisha Beltran Please scan this quick response (QR) code with your camera to view this presentation and other posters and presentations on HPN328 Copies of this slid

Harpoon Therapeutics — Technical Presentation (January 2024) on 6ix